All In Biotech

Drug Trial Radar · NCT06989112

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

DESTINY-Endometrial01: An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter, Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab vs Chemotherapy Plus Pembrolizumab as First-Line Therapy of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Mar 27, 2025

Primary completion

Jan 19, 2029

Study completion Feb 19, 2031

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Daiichi Sankyo Co., Ltd.; GOG Foundation; European Network of Gynaecological Oncological Trial Groups (ENGOT)
First posted
May 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by BICR, in participants with HER2-expressing (IHC 3+/2+), pMMR, primary advanced (Stage III/IV) or recurrent EC.

Conditions

  • Endometrial Cancer

Interventions

  • Trastuzumab deruxtecanDrug

    Experimental therapy by intravenous infusion

  • RilvegostomigDrug

    Experimental therapy by intravenous infusion

  • PembrolizumabDrug

    Immunotherapy by intravenous infusion

  • CarboplatinDrug

    Standard of Care (SoC) chemotherapy by intravenous infusion

  • PaclitaxelDrug

    Standard of Care (SoC) chemotherapy by intravenous infusion

  • DocetaxelDrug

    Standard of Care (SoC) chemotherapy by intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS), as assessed by BICRTime frame: Until progression or death due to any cause (assessed up to approximately 45 months).

Locations

256 sites in 23 countries. Site status is shown where the registry gives one.

  • Research Site

    Tucson, Arizona · Withdrawn

  • Research Site

    Little Rock, Arkansas · Recruiting

  • Research Site

    Duarte, California · Recruiting

  • Research Site

    Irvine, California · Recruiting

  • Research Site

    La Jolla, California · Recruiting

  • Research Site

    Palo Alto, California · Withdrawn

  • Research Site

    San Francisco, California · Not yet recruiting

  • Research Site

    Sylmar, California · Withdrawn

  • Research Site

    Fort Myers, Florida · Recruiting

  • Research Site

    Miami, Florida · Not yet recruiting

  • Research Site

    Miami Beach, Florida · Recruiting

  • Research Site

    Orlando, Florida · Recruiting

  • Research Site

    St. Petersburg, Florida · Recruiting

  • Research Site

    Tampa, Florida · Recruiting

  • Research Site

    West Palm Beach, Florida · Recruiting

  • Research Site

    Augusta, Georgia · Withdrawn

  • Research Site

    Honolulu, Hawaii · Withdrawn

  • Research Site

    Arlington Heights, Illinois · Recruiting

  • Research Site

    Evanston, Illinois · Recruiting

  • Research Site

    Shreveport, Louisiana · Recruiting

  • Research Site

    Baltimore, Maryland · Recruiting

  • Research Site

    Silver Spring, Maryland · Not yet recruiting

  • Research Site

    Boston, Massachusetts · Recruiting

  • Research Site

    Worcester, Massachusetts · Withdrawn

  • Research Site

    Ann Arbor, Michigan · Recruiting

  • Research Site

    Detroit, Michigan · Withdrawn

  • Research Site

    Marshall, Minnesota · Recruiting

  • Research Site

    Minneapolis, Minnesota · Recruiting

  • Research Site

    Rochester, Minnesota · Recruiting

  • Research Site

    Jackson, Mississippi · Recruiting

  • Research Site

    Springfield, Missouri · Recruiting

  • Research Site

    St Louis, Missouri · Recruiting

  • Research Site

    Las Vegas, Nevada · Withdrawn

  • Research Site

    Lebanon, New Hampshire · Recruiting

  • Research Site

    Hackensack, New Jersey · Recruiting

  • Research Site

    Albuquerque, New Mexico · Withdrawn

  • Research Site

    New York, New York · Withdrawn

  • Research Site

    New York, New York · Recruiting

  • Research Site

    New York, New York · Withdrawn

  • Research Site

    Charlotte, North Carolina · Recruiting

Showing 40 of 256 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.